Introduction {#s0005}
============

Ischemic stroke (IS) caused by either thrombosis or embolism is the most common disease leading to disability and/or death ([@bb0010], [@bb0005]). In the past decade, in addition to the known traditional risk factors such as arterial hypertension, diabetes, obesity, smoking, and dyslipidemia, other important factors including genetic variability of phenotypic profile have been identified ([@bb0015]). This genetic variability which is ethnic related is itself due to the common and uncommon risk factors for IS. However, the genes involved in the pathogenesis of this disease remain largely understudied ([@bb0020], [@bb0025]). In the pathogenesis of stroke, according to the few clinical and experimental data available, endothelial dysfunction plays a key role in vascular alteration ([@bb0030]). It has been also established that nitric oxide (NO), an endothelium-derived product of endothelial nitric oxide synthase (*eNOS*) is a potent vasodilator, anti-thrombotic, anti-inflammatory and anti proliferative, which all play important roles in the regulation of blood flow ([@bb0045], [@bb0035], [@bb0040]). Therefore, loss of function of NO contributes to the alteration of the vascular relaxation ([@bb0050]). The involvement in the physiology of the vascular system suggests that *eNOS* gene could be a potential susceptibility candidate of stroke. Located on chromosome *7q35*--*36* which contains 26 exons, the *eNOS* gene is crucial for the exchange rate of NO ([@bb0055], [@bb0060]). The polymorphism of *G894T eNO*S gene is frequently encountered in vascular diseases such as myocardial infarction, coronary spasm and arterial hypertension ([@bb0065]). Several studies have been conducted around the world on the risk of stroke with this polymorphism, but the results remain controversial, and most of these studies have focused only on the susceptibility to stroke rather than studying different models of transmission. It has been shown in some studies that *G894T eNOS* polymorphism is associated with high risk of stroke ([@bb0065]) but others found in contrast a low or moderate risk ([@bb0070]). In Morocco, to study the association between *eNOS* polymorphism and IS first, we conducted this study to better assess the *G894T eNOS* variant hand in IS. We hypothesized, in this study, that this polymorphism could have an important impact on different genetic models of IS.

Materials and methods {#s0010}
=====================

Study population {#s0030}
----------------

This is a randomized case--control study focused on a series of 165 subjects with IS recruited at the Neurology Services of the Teaching Hospital of Casablanca and Rabat between March 2009 and February 2013, and 182 healthy control subjects recruited from volunteer blood donors with no history of stroke and cognitive disorders. Informed consent has been developed for each patient and control in our study. The distribution of our patients was performed according to the international classification of TOAST (Trial of Org 10172 in Acute Stroke Treatment) after a cardiovascular neurological examination, and biological, physiological and radiological investigations (Cerebral Scanner, Doppler echography, Electrocardiogram).

DNA extraction {#s0035}
--------------

Genomic DNA was extracted from whole blood samples using the standard method with phenol/chloroform extraction and ethanol precipitation. The determination of DNA concentration was made with NanoVue Plus.

Genotyping with PCR-RFLP {#s0040}
------------------------

Genotypes of *G894T eNOS* gene was detected by PCR-RFLP as described by [@bb0075]. *G* to *T* substitution at nucleotide position 894 of *eNOS* gene creates a restriction site with *MseI* enzyme for *G894T eNOS* polymorphism. After amplification and digestion, PCR product showed one fragment of 206 bp for wild *GG* homozygous, three fragments of 206, 119 and 87 bp for *GT* heterozygous and two fragments of 119 and 87 bp for mutated *TT* homozygous ([Fig. 1](#f0005){ref-type="fig"}). The three genotypic profiles *GG*, *GT* and *TT* of *eNOS* gene obtained by PCR-RFLP were used as controls for this genotyping by high resolution melting (HRM).

Genotyping by high resolution melting (HRM) {#s0045}
-------------------------------------------

The HRM analysis on 7500 Fast Real-Time PCR (Applied Biosystems®, AB) was used to genotype *G894T eNOS* gene with an amplicon size of 206 bp. The protocol used for the reconstitution of HRM reaction was made from a reagent kit, MeltDoctor™ HRM. HRM assays were performed in a final volume of 20 μl including the MeltDoctor™ HRM Master Mix (Applied Biosystems®) which contains *SYTO9* as the DNA intercalating dye ([@bb0085], [@bb0080], [@bb0090]). Forward and reverse sequences of primers described by [@bb0075] were used for amplifications. The melting curve analysis was performed with 7500 Fast System SDS Software v2.0.1. The interpretation of *GG*, *GT* and *TT* genotypes was performed from the temperature curves in reference to the curves of the controls ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}).

Statistical analysis {#s0050}
--------------------

SPSS 11.0 software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. The law of the genotype distribution for *G894T eNOS* polymorphism among disease cases and controls were performed with Hardy--Weinberg equilibrium test. Categories of IS subtype relations to different genotypes were performed using χ^2^ test. A P value \< 0.05 was considered as significant. The association between the polymorphism of *G894T eNOS* gene and risk of IS in transmission models was evaluated using odds ratio (OR) of 95% confidence interval (CI).

Results {#s0015}
=======

By comparing HRM analysis ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}) and PCR-RFLP technique ([Fig. 1](#f0005){ref-type="fig"}) for genotyping of *G894T eNOS* gene, no discordant results were observed.

Test cases and controls were in Hardy--Weinberg equilibrium for the distribution of *G894T eNOS* polymorphism (χ^2^ = 0.30, P = 0.86; χ^2^ = 0.63, P = 0.98). The average age of patients and controls was 56.58 ± 2 and 54.15 ± 2 respectively. Older age patients (age \> 50 years) were overrepresented in our study sample compared to young subjects (age ≤ 50 years). The proportion of males was more important than that of the females. No positive correlation was seen between *G894T eNOS* polymorphism and age (P = 0.11) or sex (0.51) ([Table 1](#t0005){ref-type="table"}).

Among the IS subtypes included in our studies, atherosclerosis (93 cases) and cardioembolic (53 cases) forms were more frequent than lacunars (8 patients) and other (11 cases) forms. Statistically, no significant difference was observed between *G894T eNOS* gene and IS subtypes (P = 0.89) ([Table 2](#t0010){ref-type="table"}).

[Table 3](#t0015){ref-type="table"} shows the genotypic and allelic distribution and transmission models of *G894T eNOS* polymorphism among cases compared to controls. Genotypic frequencies found among cases and controls were 50.3% *GG*, 40.0% *GT*, and 8.0% *TT* and 61.1% *GG*, 34.6% *GT*, and 3.3% *TT* respectively. Allele frequencies of *G* and *T* of *eNOS* gene were respectively 70.3%, 29.7% and 79.4% for *G*, and 20.6% for *T* in the IS group and control group. In our study, a significant increase of risk of IS was observed in both *TT* (OR: 3.22, 95% CI = 1.27--8.18; P = 0.014) and *GT* (OR: 1.60, 95% CI = 1.02--2.52; P = 0.040) genotypes.

There was also a positive correlation between *G894T eNOS* polymorphism and IS in additive (*T* vs. *G*, OR: 1.71, 95% CI = 1.21--2.43; P = 0.003), recessive (*TT* vs. *GG* + *GT*, OR: 2.68, 95% CI = 1.08--6.70, P = 0.034) and dominant (*GT* + *TT* vs. *GG*: OR: 1.78, 95% CI = 1.16--2.73, P = 0.009) models. However, the risk was considerably higher in the recessive model than that of the other two models. So *G894T eNOS* polymorphism could be a potential genetic marker for ischemic stroke in the Moroccan population.

Discussions {#s0020}
===========

Concerning the comparison of genotyping PCR-RFLP and HRM from the same primers (size \< 300 bp), the results of *G894T eNOS* genotyping by both techniques were similar. Once genotypic profiles are known, the HRM method can be used in the rapid detection of single base sequences. This will save time with less work relative to PCR-RFLP.

NO synthesized by *eNOS*, being a potent vasodilator, anti-thrombotic, anti-inflammatory and anti-proliferative plays an important role in the regulation of blood flow. *eNOS* polymorphism plays a major role in endothelial dysfunction ([@bb0095]). *G894T eNOS* variant has been implicated in the pathogenesis of several diseases such as cardiovascular disease and erectile dysfunction ([@bb0100], [@bb0110], [@bb0105]). However, the results of various studies on this variant as a factor in genetic predisposition to IS stay contradictory ([@bb0070]). We carried out this work in order to better assess the interaction between *G894T eNOS* polymorphism and IS in the Moroccan population. The large number of IS subjects aged ≥ 50 years and male in our study sample was in conformity with what has been reported in the literature that IS is a pathology that affects both sexes at any time of life but the elderly (50 years or older) are more affected than younger subjects with a male predominance ([@bb0115]). Our data showed no positive association between *G894T* polymorphism of *eNOS* gene and demographic characteristics (age and gender). This result is consistent with those that have been found by [@bb0120] and [@bb0125]. They respectively found in German and Tunisian populations that association of this polymorphism with age and gender was independent.

We observed no significant difference in the distribution of *G894T eNOS* polymorphism and IS subtypes. This result was similar to what has been obtained by [@bb0130], [@bb0135], [@bb0140] and [@bb0145]. The first reported that *G894T eNOS* gene is not associated with an increased risk of IS subtypes in Caucasian and African American populations. Markus et al. found in a British population that *G894T eNOS* variant was not associated with ischemic stroke secondary to atherosclerosis forms. In the study by Hassan, this polymorphism was associated with a reduction of ischemic stroke risk secondary to lacunar infarction forms. Moreover, MacLeod et al. reported in a French population that the effect of this polymorphism has no impact on IS subtypes. By contrast, Elbaz et al. found a statistically significant association between *G894T eNOS* gene and IS lacunar forms ([@bb0150]). These discrepancies concerning the relation between *G894T eNOS* variant and the risk of ischemic stroke subtypes could be linked to several factors, including methodological differences between studies, the sample size, the frequency of subtypes in different populations and early diagnosis of radiological IS.

Regarding the association between *G894T* eNOS polymorphism and the risk of ischemic stroke, the results of our study suggest that *GT* and *TT* genotypes were significantly associated with ischemic stroke. This data was similar to that observed by Saidi et al. who reported on a Bahrain population increased risk of ischemic stroke (P \< 0001 for the two genotypes) ([@bb0125]). Berger et al. found the same result in a German population where the risk of *CT* and *TT* genotypes was 1.16 (P = 0.03) and 0.01 (P = 0.01) respectively ([@bb0120]).

Concerning the relation between *G894T eNOS* polymorphism and IS in different models, the present study also revealed that the *G894T eNOS* gene was significantly associated with an increased risk of ischemic stroke in recessive, dominant and additive models, where a strong association was observed with the first model (OR = 2.68) compared to the other two models. These are consistent with those reported by Saidi et al. on a Bahrain population, in which the three models seem to be involved in the pathogenesis of IS ([@bb0125]). Similarly, Wang et al., in a meta-analysis of several populations (Asia, Turkey) and Berger et al. (German population) concluded that recessive and dominant genetic models were associated with a high risk of IS for *G894T eNOS* but not with the recessive model ([@bb0120], [@bb0065]). However, in a specific subgroup analysis of Chinese population, the results were similar ([@bb0065]) ([Table 4](#t0020){ref-type="table"}). Interestingly, as the conclusion of another meta-analysis in a well-diversified population, [@bb0070] reported that three genetic models were moderately associated with risk of ischemic stroke ([Table 4](#t0020){ref-type="table"}).

This contradiction about *G894T eNOS* polymorphism and IS in a recessive model could be explained by the difference in sample sizes and genetic variability of ethnicities ([Table 3](#t0015){ref-type="table"}). The most common problem in association studies is the inconsistency of data due to different models of inheritance ([@bb0155]). Thus, deep study of the genetic predisposition behind these different models of transmission is required to properly elucidate the hereditary nature of the polymorphisms. When the inheritance is unknown with two alleles of single genetic variant, dominant, recessive, and additive models may have complex characters ([@bb0155], [@bb0160]). To avoid one genetic model, we presented here an analysis of three different models. If the risk is the same for *G894T* heterozygous carrying one copy of *894T* mutated allele, as for homozygosity, the underlying model is dominant. For the recessive model, two copies of *894T eNOS* gene are necessary so that risk is different from the basis risk. The risk in subjects carrying two copies of *894T* is double the risk in heterozygous cases, which is the additive genetic model ([@bb0165], [@bb0155]). In addition, the maximum power is obtained, when the inherited model is unknown with codominant model and one or all three genetic models are tested together.

Conclusion {#s0025}
==========

Although the PCR-RFLP method remains laborious and requires plenty of time, our results suggested that HRM is a simple, fast, reliable and profitable test, which allows genotyping of *G894T eNOS* gene. In this study, we showed that *G894T eNOS* polymorphism could play its part by endothelial dysfunction process in the onset of IS in a Moroccan population. It would be important in future studies to increase the sample size on the one hand and on the other hand to measure the impact of this polymorphism at the clinical level. In addition, it will be important to add biochemical tests of NO in order to better understand this polymorphism\'s direct relation with ischemic stroke.
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![PCR-RFLP analysis on agarose gel of *G894T eNOS* polymorphism. Lanes 1, 2, and 4 represent GG homozygous wild-type; lanes 5, 6, and 7 represent GT heterozygous and lane 3, TT homozygous mutated.](gr1){#f0005}

![Aligned melting curve HRM analysis of *G894T eNOS* polymorphism. Blue---GG homozygous wild type, red---GT heterozygous mutant and green---TT homozygous mutant.](gr2){#f0010}

![Difference plots of HRM analysis of *G894T eNOS* polymorphism. Blue---*GG* homozygous wild type, red---*GT* heterozygous mutant and green reference---*TT* homozygous mutant.](gr3){#f0015}

###### 

Frequencies of *G894T eNOS* polymorphism according to age, gender and subtypes in ischemic stroke subjects.

  --------------------------------------------------------------------------------------
  IS characteristic   N     *G894T eNOS* polymorphism   P value\                  
                                                        (P \< 0.05)               
  ------------------- ----- --------------------------- ------------- ----------- ------
  Age                 165                                                         0.11

   ≤ 50 years         47    21 (44.7)                   24 (51.1)     2 (4.3)     

   \> 50 years        118   62 (52.5)                   42 (35.6)     14 (11.9)   

  Gender              165                                                         0.51

   Female             74    38 (51.4)                   31 (41.9)     5 (6.8)     

   Male               91    45 (49.5)                   35 (38.5)     11 (12.1)   
  --------------------------------------------------------------------------------------

N: total number, *GG eNOS* wild genotypes, *GT eNOS* variant heterozygous, *TT eNOS* variant homozygous.

###### 

Genotype frequencies of *G894T eNOS* gene according to ischemic stroke subtype.

  Genotypes   TOAST classification (%)                          
  ----------- -------------------------- ----------- ---------- ----------
  GG          45 (48.4)                  29 (54.7)   4 (50.0)   5 (45.5)
  *GT*        38 (40.9)                  21 (39.6)   3 (37.5)   4 (36.4)
  *TT*        10 (10.8)                  3 (5.7)     1 (12.5)   2 (18.2)

Chi-square test of all IS subtypes (χ^2^ = 2.27, P = 0.89).

*GG eNOS* wild genotypes, *GT eNOS* variant heterozygous, *TT eNOS* variant homozygous, TOAST (Trial of Org 10172 in Acute Stroke Treatment).

###### 

Genotype and allele frequencies of *G894T eNOS* polymorphism in patients with ischemic stroke and controls.

  ---------------------------------------------------------------------------------------------------------------------------------------
  Genotypes/alleles                              Cases (%)\   Control (%)\   OR (95% CI)         P value
                                                 N = 165      N = 182                            
  ---------------------------------------------- ------------ -------------- ------------------- ----------------------------------------
  *GG*                                           83 (50.3)    117 (64.3)     1                   

  *GT*                                           66 (40.0)    58 (31.9)      1.60 (1.02--2.52)   0.040[a](#tf0005){ref-type="table-fn"}

  *TT*                                           16 (8.0)     7 (3.8)        3.22 (1.27--8.18)   0.014[a](#tf0005){ref-type="table-fn"}

  *GG* + *GT*[b](#tf0010){ref-type="table-fn"}   149 (90.3)   175 (96.2)     1                   

  *TT*                                           16 (9.7)     7 (3.8)        2.68 (1.08--6.70)   0.034[a](#tf0005){ref-type="table-fn"}

  *GG*[c](#tf0015){ref-type="table-fn"}          83 (50.3)    117 (64.3)     1                   

  *GT* + *TT*                                    82 (46.7)    65 (35.7)      1.78 (1.16--2.73)   0.009[a](#tf0005){ref-type="table-fn"}

  *G*[d](#tf0020){ref-type="table-fn"}           232 (70.3)   292 (80.2)     1                   

  *T*                                            98 (29.7)    72 (19.8)      1.71 (1.21--2.43)   0.003[a](#tf0005){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------------------------------------------------------

N: Number, OR: odds ratio, CI: confidence interval, P \< 0.05, vs.: versus, Ref.: reference, %: percentage.

Significant.

*TT* vs. *GG* + *GT* (recessive model) for *G894T eNOS*.

*GT* + *TT* vs. *GG* (dominant model) for *G894T eNOS*.

*T* vs. *G* (additive model) for *G894T eNOS*.

###### 

Summary of studies of *G894T eNOS* polymorphism and ischemic stroke in genetic models.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Additive model\     Dominant model\                              Recessive model\       Authors                                                                                                        
  *T* vs. *G*         *GT* + *TT* vs. *GG*                         *TT* vs. *GG* + *GT*                                                                                                                  
  ------------------- -------------------------------------------- ---------------------- -------------------------------------------- -------------------- -------------------------------------------- -------------------
  1.16 (1.05--1.13)   0.003[a](#tf0025){ref-type="table-fn"}       2.26 (1.2--4.66)       0.014[a](#tf0025){ref-type="table-fn"}       2.58 (0.05--13.62)   0.26                                         [@bb0120]

  1.06 (0.99--1.13)   0.06                                         1.07 (0.99--1.55)      0.11                                         1.11 (0.97--1.28)    0.12                                         Tao et al. (2009)

  1.97 (1.59--2.43)   \< 0.0001[a](#tf0025){ref-type="table-fn"}   2.51 (1.86--3.39)      \< 0.0001[a](#tf0025){ref-type="table-fn"}   2.24 (1.40--3.42)    \< 0.0001[a](#tf0025){ref-type="table-fn"}   [@bb0125]

  1.27 (1.13--1.42)   0.000[a](#tf0025){ref-type="table-fn"}       1.30 (1.15--1.49)      0.000[a](#tf0025){ref-type="table-fn"}       1.273 (0.85--1.91)   0.25                                         [@bb0065]

  1.34 (1.11--1.60)   0.000[a](#tf0025){ref-type="table-fn"}       1.34 (1.10--1.62)      0.000[a](#tf0025){ref-type="table-fn"}       1.27 (0.85--1.91)    0.074                                        [@bb0065]

  1.71 (1.21--2.43)   0.003                                        1.78 (1.16--2.73)      0.009[a](#tf0025){ref-type="table-fn"}       2.68 (1.08--6.70)    0.034[a](#tf0025){ref-type="table-fn"}       Our study 2014
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OR: odds ratio, CI: confidence interval, P \< 0.05.

Significant.

[^1]: Moroccan group for stroke research.
